Literature DB >> 24474145

Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.

Alexander Dömling1, Tad A Holak.   

Abstract

No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antibodies; cancer immunotherapy; immune checkpoint; programmed death 1; protein-protein interactions

Mesh：

Substances：

Year:  2014        PMID： 24474145      PMCID： PMC4104593          DOI： 10.1002/anie.201307906

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


  12 in total

1.  The hybridoma revolution: an offshoot of basic research.

Authors:  C Milstein
Journal:  Bioessays       Date:  1999-11       Impact factor: 4.345

2.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

3.  New checkpoint inhibitors ride the immunotherapy tsunami.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

4.  Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alexander M M Eggermont
Journal:  Eur J Cancer       Date:  2013-07-29       Impact factor: 9.162

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 6.  Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Authors:  Omid Hamid; Richard D Carvajal
Journal:  Expert Opin Biol Ther       Date:  2013-02-19       Impact factor: 4.388

7.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; S L Topalian; A E Chang; D J Schwartzentruber; P Aebersold; S Leitman; W M Linehan; C A Seipp
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.

Authors:  S A Sherwin; J A Knost; S Fein; P G Abrams; K A Foon; J J Ochs; C Schoenberger; A E Maluish; R K Oldham
Journal:  JAMA       Date:  1982-11-19       Impact factor: 56.272

10.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962
View more
  19 in total

Review 1.  Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Authors:  Markella Konstantinidou; Tryfon Zarganes-Tzitzikas; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-23       Impact factor: 15.336

Review 2.  Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.

Authors:  Jiao Kong; Ya-Qiu Long
Journal:  RSC Med Chem       Date:  2022-01-15

3.  Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).

Authors:  Tryfon Zarganes-Tzitzikas; Markella Konstantinidou; Yongzhi Gao; Dobroslawa Krzemien; Krzysztof Zak; Grzegorz Dubin; Tad A Holak; Alexander Dömling
Journal:  Expert Opin Ther Pat       Date:  2016-07-06       Impact factor: 6.674

4.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Authors:  Katarzyna Magiera-Mularz; Lukasz Skalniak; Krzysztof M Zak; Bogdan Musielak; Ewa Rudzinska-Szostak; Łukasz Berlicki; Justyna Kocik; Przemyslaw Grudnik; Dominik Sala; Tryfon Zarganes-Tzitzikas; Shabnam Shaabani; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2017-09-26       Impact factor: 15.336

5.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

Review 6.  Nanotechnology for protein delivery: Overview and perspectives.

Authors:  Mikyung Yu; Jun Wu; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2015-10-13       Impact factor: 9.776

Review 7.  How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Alexander Dömling
Journal:  ChemMedChem       Date:  2015-12-16       Impact factor: 3.466

8.  A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects.

Authors:  Wei-Yun Lai; Bo-Tsang Huang; Jen-Wei Wang; Pei-Ying Lin; Pan-Chyr Yang
Journal:  Mol Ther Nucleic Acids       Date:  2016-12-13

9.  Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists.

Authors:  Roberto Butera; Marta Ważyńska; Katarzyna Magiera-Mularz; Jacek Plewka; Bogdan Musielak; Ewa Surmiak; Dominik Sala; Radoslaw Kitel; Marco de Bruyn; Hans W Nijman; Philip H Elsinga; Tad A Holak; Alexander Dömling
Journal:  ACS Med Chem Lett       Date:  2021-04-28       Impact factor: 4.345

Review 10.  The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.

Authors:  Sijia Ren; Xinxin Xiong; Hua You; Jianfei Shen; Penghui Zhou
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.